Promising News for Triple-Negative Breast Cancer

Promising News for Triple-Negative Breast Cancer

Women with triple-negative breast cancers have two strikes against them: A lack of effective therapies and a high disease-specific mortality rate. The p53 mutation may prove to be the Achilles' heel of this very aggressive disease. In a review article, Italian oncologists discuss the current and novel agents with potential activity against aberrant p53 signaling that may lead to at last successful, targeted therapy for the triple-negative subtype. 

RESULT:  Targeting triple negative breast cancer: is p53 the answer? 
Cancer Treatment Reviews (PubMed) | Aug 01, 2013 (Free abstract. Full text $32)

A trio of global, phase III trials (E2100, AVADO and RIBBON-1) demonstrated the survival benefits of first-line therapy with bevacizumab (Avastin) in HER2-negative metastatic breast cancer, but how do the results hold up when the data are pooled together? Fairly well, according to a meta-analysis by international researchers. The bevacizumab-chemotherapy combo did consistently boost response rates and overall survival, including for patients with triple-negative breast cancers. 

RESULT: First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
Annals of Oncology | Jul 23, 2013 (FREE FULL TEXT)

Loading comments...
Please Wait 20 seconds or click here to close